Abstract: The present invention provides a method for generating somatic stem cells out of differentiated cells, somatic stem cells obtained by this method and a vector or composition for use in this method.

Abstract: The present invention relates to the expression of two genes, CyclinG2 and Sharp1, which correlates with prognosis in individuals having breast cancer. Specifically, this invention provides a method to stratify samples from breast cancer patients in a high or low recurrence risk in the years following primary tumor removal. This classification can be achieved through the analysis of protein or mRNA expression levels for the two identified genes. The invention also illustrates how CyclinG2 and Sharp1 have been identified in mammary cancer cell lines and validated in a large cohort of human patients as powerful metastasis predictors.

Abstract: The present invention relates to the expression of two genes, CyclinG2 and Sharp1, which correlates with prognosis in individuals having breast cancer. Specifically, this invention provides a method to stratify samples from breast cancer patients in a high or low recurrence risk in the years following primary tumor removal. This classification can be achieved through the analysis of protein or mRNA expression levels for the two identified genes. The invention also illustrates how CyclinG2 and Sharp1 have been identified in mammary cancer cell lines and validated in a large cohort of human patients as powerful metastasis predictors.

Abstract: The present invention relates to molecules preferably of polypeptide nature with negative regulatory activity on the amount or activity of TGF-? through direct interaction with pro-TGF-?, and containing as active region a cysteine-rich polypeptide sequence defined as “EMI domain”, or its subfragments, wherein said “EMI domain” has at least 25% sequence homology to the ID NO2 sequence for pharmaceutical use. Even more preferably said polypeptide sequence consists of the EMI domain of the following proteins: emilin-1, emilin-2 and/or multimerin-2 or their subfragments having a length of at least 6 amino acids, capable of inhibiting the conversion of pro-TGF? to mature TGF? as anti-hypertensive drugs and polypeptides active on the cardiovascular system.